S12 - MS Therapeutics and MRI Outcomes

Event Time: Monday April 24, 2017 1:00 pm to 3:00 pm
Topic(s): MS and CNS Inflammatory Disease
Director(s):
Description: A group of abstracts covering a similar topic presented in an oral format. Presentations are eight minutes in length with four minutes of question and answer. Each session concludes with 25 minutes of a discussant bringing additional context to one or more of the abstracts.
Completion Message:
CME Credits: 2
Core Competencies:

Abstract Presenters

Start Time Pub. Title Presenter
1:00 PM 001 Daclizumab Reduced Brain Tissue Loss Compared With Intramuscular Interferon Beta-1a in the 2-3 Year DECIDE Study John Rose, MD, FAAN
Disclosure:
Dr. Rose has received research support from Biogen.

1:12 PM 002 MRI Outcomes at Seven Years in Relapsing-Remitting Multiple Sclerosis Patients Treated With Delayed-release Dimethyl Fumarate in DEFINE, CONFIRM, and ENDORSE Douglas L Arnold, MD
Disclosure:
Dr. Arnold has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Biogen, F. Hoffmann-La Roche Ltd, MedDay, MedImmune, Mitsubishi, Novartis, Receptos/Celgene, Sanofi-Aventis. Dr. Arnold has received compensation for serving on the Board of Directors of NeuroRx Research.

1:24 PM 003 Alemtuzumab Reduces the Rate of Brain Volume Loss in RRMS Patients Over 4 Years Following Switch From SC IFNB-1a: CARE-MS Extension Study Daniel Pelletier, MD
Disclosure:
Dr. Pelletier has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck Serono, Novartis, Roche, and Sanofi. Dr. Pelletier has received research support from Biogen, Merck Serono, Novartis, Roche, and Sanofi.

1:36 PM 004 Feasibility of brain atrophy measurement in clinical routine: Results from MS-MRIUS, a longitudinal observational, multicenter real-world outcome study in RRMS patients Michael Dwyer, MD, PhD
Disclosure:
Dr. Zivadinov has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Serono, Genzyme-Sanofi, Claret Medical, Celgene and Novartis. Dr. Zivadinov has received research support from RZ received financial support for research activities from Genzyme-Sanofi, Novartis, Claret Medical, Intekrin-Coherus and Quintiles IMS.

1:48 PM 005 Brain Volume Loss Correlates With Long-term Disability Worsening in Patients With MS: SIENA Analysis of TEMSO MRI Data Till Sprenger
Disclosure:
Dr. Sprenger has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Actelion, Novartis, Sanofi Genzyme, Electrocore, Merck, TEVA.

2:00 PM 006 Alemtuzumab Decreased MRI Disease Activity Through 6 Years in Patients With Highly Active RRMS and an Inadequate Response to Prior Therapy: CARE-MS II Extension Study Alex Rovira
Disclosure:
Dr. Rovira has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer, Biogen, Bracco, Novartis, Sanofi, and Stendhal.

2:12 PM 007 Alemtuzumab Decreased MRI Disease Activity Over 4 Years in Patients Who Switched From SC IFNB-1a: CARE-MS II Extension Study 4-Year Follow-up Daniel Pelletier, MD
Disclosure:
Dr. Pelletier has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck Serono, Novartis, Roche, and Sanofi. Dr. Pelletier has received research support from Biogen, Merck Serono, Novartis, Roche, and Sanofi.

2:24 PM 008 Rapid Onset of Ocrelizumab Suppression of Brain MRI Activity in Relapsing-Remitting Multiple Sclerosis Frederik Barkhof
Disclosure:
Dr. Barkhof has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Apitope Ltd., GeNeuro, Biogen Idec, Sanofi-Genzyme, Janssen Research, Merck-Serono, Novartis, IXICO Ltd, Roche and TEVA. Dr. Barkhof has received research support from Grants from AMYPAD (IMI), EuroPOND (H2020), UK MS Society, Dutch MS Society, PICTURE (IMDI-NWO), NIHR UCLH Biomedical Research Centre (BRC) and ECTRIMS-MAGNIMS.

Register Now

Related Courses